FancyMeds Review

What FancyMeds charges

• Semaglutide: $199 — billed every four weeks, struck through from $249; the same twelve-week treatment is $499 as a one-time payment
• Tirzepatide: $299 — billed every four weeks, struck through from $399; the same twelve-week treatment is $799 as a one-time payment
• PT-141: $199 — billed every four weeks; the same eight-week treatment is $375 as a one-time payment
• Glutathione: $179 — billed every four weeks; the same eight-week treatment is $339 as a one-time payment

The letter names this website

A 2025 federal warning letter is filed against Fancy Meds, LLC dba Fancy Meds, and its opening line cites this seller's own domain.

The letter was missed on a first pass because the brand was queried as one word while the federal table spells the entity with a separator, so a real letter read as an absence until the screen was rebuilt to normalise both sides.

That is the single most load-bearing fact on this page, and it sits underneath everything the site does well.

It names its pharmacies, and one of them carries its own letter

Its terms say it provides "prescription fulfillment services via pharmacies including Red Rock Pharmacy and EHT Pharmacy LLC dba Curexa", one of them given by both legal entity and trading name.

Curexa holds a separate 2023 federal warning letter of its own, filed over compounding and adulterated drug products. That letter belongs to the pharmacy, not to this seller, and is not part of the seller's own record.

Red Rock Pharmacy carries none. The seller's own words on category are that "Compounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed."

Each product page carries the other drug's price

The semaglutide page contains a priced block headed for tirzepatide, and the tirzepatide page contains a priced block for semaglutide.

A reader skimming one page can leave with the number that belongs to the other product, and nothing on the card warns them.

The assignment used here was confirmed a second way against the site's own comparison table, which prices both molecules side by side per four weeks.

Two ways to pay, and a state answer that never renders

Every product is sold as an instalment billed every four weeks and as a single payment for the whole treatment, with the titration schedule and treatment length printed beside each figure.

Four weeks is not a month, though: thirteen instalments fall in a year rather than twelve, so the instalment reads cheaper than it bills.

Its own FAQ heading asks where its telehealth services are available and the served page prints no answer beneath it, so no coverage claim is credited here.

FDA disclosure

FancyMeds received an FDA warning letter issued September 2025. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.

How we verified this

• Read each product page in document order and confirmed the cross-sell block belongs to the other drug, then assigned every figure to the product its own page and the site's comparison table both support.
• Recorded the instalment and the one-time total separately, because they buy the same treatment on different terms.
• Confirmed its state FAQ heading has no answer in the served page rather than assuming one was hidden behind a control.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Confirmed the federal warning letter from its own opening line, which names this seller's website, and confirmed the separate pharmacy letter the same way and attributed it to Curexa rather than to the seller.